Correlates of adiponectin in hepatitis C-infected children: The importance of body mass index

Journal of Pediatric Gastroenterology and Nutrition

Volumn 60, Issue 2, 2015, Pages 165-170

  Delgado Borrego, Aymin ^a   Gonzalez Peralta, Regino P ^d   Raza, Roshan ^b   Negre, Betania ^a   Goodman, Zachary D ^e   Jonas, Maureen M ^b   Chung, Raymond T ^c   Ludwig, David A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

adiponectin; body mass index; hepatitis C; pediatric

Indexed keywords

ADIPONECTIN;

ADOLESCENT; ANTHROPOMETRY; ARTICLE; BODY MASS; CHILD; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS C; HUMAN; INFECTION RISK; LABORATORY TEST; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; AGE; BLOOD; CHRONIC HEPATITIS C; FATTY LIVER; LIVER CIRRHOSIS; PRESCHOOL CHILD; TRANSMISSION;

HEPATITIS C VIRUS;

ADIPONECTIN; ADOLESCENT; AGE FACTORS; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE;

EID: 84922287664     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000604     Document Type: Article

References (50)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42
2. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51: 729-33
3. Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet 2003; 362: 2095-100
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50
5. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62
6. Badizadegan K, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28: 1416-23
7. Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C trial. Hepatology 2008; 47: 836-43
8. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-32
9. Jonsson JR, Moschen AR, Hickman IJ, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005; 43: 929-36
10. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100
11. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-53
12. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9
13. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-70
14. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83
15. Wedemeyer I, Bechmann LP, Odenthal M, et al. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol 2009; 50: 140-9
16. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachlorideinduced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-807
17. Palmer C, Hampartzoumian T, Lloyd A, et al A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology 2008; 48: 374-84
18. Zografos TA, Liaskos C, Rigopoulou EI, et al. Adiponectin: a new independent predictor of liver steatosis and response to IFN-Alpha treatment in chronic hepatitis C. Am J Gastroenterol 2008; 103: 605-14
19. Corbetta S, Redaelli A, Pozzi M, et al. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection. Eur J Clin Invest 2011; 41: 898-905
20. Kaser S, Moschen A, Kaser A, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 2005; 258: 274-80
21. Korah TE, El-Sayed S, Elshafie MK, et al. Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. World J Hepatol 2013; 5: 74-81
22. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-8e451
23. Murray KF, Rodrigue JR, Gonzalez-Peralta RP, et al. Design of the PEDS-C trial: pegylated interferon /- ribavirin for children with chronic hepatitis C viral infection. Clin Trials 2007; 4: 661-73
24. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5
25. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85
26. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9
27. Bedossa P, Poynard T An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93
28. Percentile Data Files With LMS Values. http://www.cdc.gov/growth charts/percentile-data-files.htm. Published 2008. Accessed January 17, 2014
29. Wang AY, Hickman IJ, Richards AA, et al. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol 2005; 100: 2717-23
30. Jaleel A, Aheed B, Jaleel S, et al. Association of adipokines with obesity in children and adolescents. Biomarkers Med 2013; 7: 731-5
31. Kardas F, Kendirci M, Kurtoglu S. Cardiometabolic risk factors related to vitamin d and adiponectin in obese children and adolescents. Int J Endocrinol 2013; 2013: 503270
32. Gil-Campos M, Canete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963-74
33. Calcaterra V, De Amici M, Klersy C, et al. Adiponectin, IL-10 and metabolic syndrome in obese children and adolescents. Acta Biomed 2009; 80: 117-23
34. Kelly AS, Steinberger J, Kaiser DR, et al. Oxidative stress and adverse adipokine profile characterize the metabolic syndrome in children. J Cardiometab Syndr 2006; 1: 248-52
35. Delgado-Borrego A, Casson D, Schoenfeld D, et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004; 77: 703-10
36. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-6
37. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus downregulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-508
38. Delgado-Borrego A, Jordan SH, Negre B, et al. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8: 458-62
39. Baron AD. Impaired glucose tolerance as a disease. Am J Cardiol 2001; 88: 16H-9H
40. Zavaroni I, Bonini L, Gasparini P, et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism 1999; 48: 989-94
41. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25: 1135-41
42. Lakka HM, Lakka TA, Tuomilehto J, et al. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2000; 160: 1160-8
43. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-Aged men. JAMA 2002; 288: 2709-16
44. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 2003; 125: 1695-704
45. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28-34
46. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-Analysis of individual patient data. Gastroenterology 2006; 130: 1636-42
47. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90
48. Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut 2005; 54: 903-6
49. Delgado-Borrego A, Healey D, Negre B, et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2010; 51: 191-7
50. Bottner A, Kratzsch J, Muller G, et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004; 89: 4053-61